研究单位：[1]Department of Infectious Disease,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology Wuhan,Hubei,China,430030[2]Shulan(Hangzhou) hospitai Hangzhou,China[3]First Affiliated Hospital of Nanchang University Nanchang,China[4]Shanghai public health clinic Shanghai,China[5]General Hospital of The Yangtze River Shipping Wuhan,China[6]The Seventh Hospital of Wuhan Wuhan,China[7]Xiangya Hospital of Central South University Xiangya,China
研究目的：
This study is a multi-center, prospective, real-world study, males and non-pregnant, non-lactating female HBeAg positive or negative patients (above 18 years of age) who were mono-infected with HBV, either NA treatment-naïve or treatment-experienced, but TAF naïve will be enrolled in this study, and they will be treated with TAF, alone or in combination with other HBV antivirals. During 36 months of treatment, efficacy and safety will be evaluated.
